|

Isatuximab Clinical Trials

19 actively recruiting trials across 10 locations

Also known as: Bortezomib, Dexamethasone, Lenalidomide, Pomalidomide, SAR650984, Sarclisa, Sarclisa®

Other8 trials

Clinical Trial for Autologus NK Cells Alone or in Combination With Isatuximab as Maintenance for Multiple Myeloma
Phase 2
Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma
Phase 3
Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma
Phase 3
Isatuximab Plus Pomalidomide and Dexamethasone Association for Patients With AL Amyloidosis Not in VGPR or Better After Any Previous Therapy
Phase 2
Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma
Phase 2
Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia
Phase 2
Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients
Phase 2
Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy
Phase 2

Milwaukee, Wisconsin2 trials

Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency

Froedtert Hospital & the Medical College of Wisconsin

Phase 2
Elimination of Minimal Residual Disease After Transplant

Froedtert Hospital & the Medical College of Wisconsin

Phase 2

La Jolla, California1 trial

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Scripps Clinic Torrey Pines

Phase 1

Los Angeles, California1 trial

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Valkyrie Clinical Trials

Phase 1/2

Chicago, Illinois1 trial

Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma

University of Illinois at Chicago

Phase 2

Boston, Massachusetts1 trial

Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma

Massachusetts General Hospital

Phase 2

Detroit, Michigan1 trial

Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma

Karmanos Cancer Institute

Phase 2

Basking Ridge, New Jersey1 trial

Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 2

Chapel Hill, North Carolina1 trial

Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma

University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center

Phase 2

Houston, Texas1 trial

Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients

M D Anderson Cancer Center

Phase 2

Salt Lake City, Utah1 trial

Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma

Huntsman Cancer Institute at the University of Utah

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.